Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients

NCT ID: NCT01413815

Last Updated: 2022-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 269 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2012-09-30

Brief Summary

The aim of the study is to test whether pre-operative oral supplementation with L-arginine results in a significant reduction of peri-operative cardiovascular complication rate in unselected patients undergoing major abdominal or thoracic (non-cardiac) surgery. The second aim of the study is to assess whether pre-operative determination of plasma ADMA levels allows to identify patients who are at high risk of experiencing a peri-operative complication, and whether this subgroup of patients profits specifically from pre-operative L-arginine supplementation.

Detailed Description

Patients will be recruited for this study from the participating Departments. In a previous study (protocol no. UKE-KP 2002/006) we investigated the predictive role of ADMA (asymmetric dimethylarginine) for peri-operative complications in unselected patients undergoing major surgery. The major result of that study was that patients with pre-operative ADMA plasma level within the highest quartile of the distribution had a significantly elevated risk of experiencing a serious peri-operative complication within a period of 30 days after the surgical intervention. These data have been published [Maas et al. 2007]. As ADMA competitively displaces L-arginine from the enzyme, NO synthase, it is expected that the adverse cardiovascular effects of high ADMA levels can be antagonized by supplemental L-arginine. Therefore, the present study was designed to specifically address the question whether dietary supplementation with L-arginine before the surgery, aiming at replenishing the body's L-arginine stores, may help to reduce the peri- operative complication rate. Another aim is to assess whether this occurs in all patients or specifically in the subgroup with elevated baseline ADMA levels.

Study participants will be recruited from patients who routinely visit the outpatient clinic at the participating Departments of Anesthesiology and Intensive Care in advance of their planned surgical intervention. Patients usually visit the clinic between five working days in advance of the scheduled time of surgery, or they are admitted to in-patient treatment one or two days before the surgery. They will be informed about the scope and aim of the study, and after having given their informed consent, patients will receive L-arginine dietary supplements or corresponding placebo according to randomisation plan for the time until surgery. The last dosage of the L-arginine supplements will be taken in the morning of the surgery, dissolved in a glass of tap water that patients ware required to drink with premedication for anesthesia. Blood samples to measure plasma L-arginine and ADMA levels will be taken at the time of inclusion, in the morning before scheduled surgery, and on days 1 and 3 after the surgery and will together with additional safety parameter not exceed 80ml. No administration of study product will occur after surgery.

After surgery having taken place, patients will be monitored daily for as long as they remain being treated as in-patients, and all clinical events, changes in laboratory parameters, and apparatively performed clinical tests as scheduled according to clinical routine will be documented. No additional clinical treating will be performed on study participants, except the blood samples that will be taken as described above. After discharge, patients will be followed-up telephonically, for the last time at 30 days after the date of surgery. All clinical events occurring in this period will be recorded. In addition, changes in laboratory values, ECG recordings, and other apparative diagnostic measures will be checked for possible complications, and also be recorded.

Conditions

Cardiovascular Complication

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

L-arginine

L-Arginine

Group Type: ACTIVE_COMPARATOR

L-arginine

Intervention Type: DIETARY_SUPPLEMENT

3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).

corn starch

Placebo: Corn Starch

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)

Interventions

L-arginine

3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).

Intervention Type: DIETARY_SUPPLEMENT

Placebo

3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)

Intervention Type: OTHER

Other Intervention Names

corn starch

Eligibility Criteria

Inclusion Criteria

• male and female subjects aged between 30 and 75 years;
• scheduled major thoracic (non-cardiac), abdominal, or two cavity surgery;
• ASA risk class II- IV;
• efficient birth control for women in child-bearing age;
• signed written informed consent form.

Exclusion Criteria

• participation in a clinical study within the last 3 months before inclusion into the present study;
• high allergic tendency in the medical history at the investigators discretion;
• patients with known diabetic retinopathy;
• previous abuse of drugs or alcohol;
• pregnancy or nursing;
• any severe consuming disease (malignant or non-malignant) that reduces the patient's life expectancy to a level which makes it uncertain that the patient would survive the 30 day period even without surgery;
• any somatic or psychic disease that may hamper participation in the study or compliance;
• active liver disease or hepatic failure (serum AST or ALT >1.5-fold above the upper limit of the normal range);
• severe renal failure (calculated creatinine clearance < 30 ml/min [Cockcroft-Gault formula]), nephrotic syndrome or dysproteinemia;
• previous intolerance of L-arginine or L-citrulline.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rainer H. Böger, Professor

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Hamburg-Eppendorf

Locations

Klinik für Anästhesiologie,Städtisches Klinikum Lüneburg

Lüneburg, Lower Saxony, Germany

Institut für Experimentelle und Klinische Pharmakologie,Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie,Kath. Marienkrankenhaus gGmbH

Hamburg, , Germany

Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Klinik für Anästhesie und operative Intensivmedizin,Asklepios Klinik Nord, Standort Heidberg

Hamburg, , Germany

Countries

Germany

References

Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hiltmeyer N, Haddad M, Kloss T, Standl T, Boger RH. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med. 2007 Aug;35(8):1876-81. doi: 10.1097/01.CCM.0000277038.11630.71.

Reference Type: BACKGROUND

PMID: 17581491 (View on PubMed)

Appel D, Boger R, Windolph J, Heinze G, Goetz AE, Hannemann J. Asymmetric dimethylarginine predicts perioperative cardiovascular complications in patients undergoing medium-to-high risk non-cardiac surgery. J Int Med Res. 2020 Aug;48(8):300060520940450. doi: 10.1177/0300060520940450.

Reference Type: RESULT

PMID: 32842812 (View on PubMed)

Other Identifiers

UKE-KP 2009/001

Identifier Type: -

Identifier Source: org_study_id